Literature DB >> 8554146

Cryoablation of unresectable malignant liver tumors.

M Shafir1, R Shapiro, M Sung, R Warner, A Sicular, A Klipfel.   

Abstract

BACKGROUND: Unresectable malignant liver tumors, particularly metastases of gastrointestinal origin, are rapidly lethal in a vast majority of patients, regardless of treatment. PATIENTS AND METHODS: We evaluated 58 patients by laparoscopy and/or laparotomy. Thirty-nine were treated with cryoablation of liver tumors using a liquid-nitrogen cryoprobe delivering a tumoricidal temperature of -196 degrees C with intraoperative ultrasound monitoring. Histologic evaluation showed that 25 patients had colorectal metastases, 3 had gastric tumors, 4 hepatocellular carcinomas, 6 carcinoids, and 1 gastrinoma.
RESULTS: All patients who received complete cryoablation are alive with a mean follow-up of 14 months. Five whose treatment could not be completed died between 3 and 9 months postoperatively. Thirteen patients (28%) have recurrent disease and 20 (51%) have no evidence of disease. There were no operative mortalities. Postoperative transient elevation of liver function tests and thrombocytopenia were noted. All patients received postoperative chemotherapy.
CONCLUSION: Cryoablation is an active and safe treatment for advanced liver malignancies.

Entities:  

Mesh:

Year:  1996        PMID: 8554146     DOI: 10.1016/s0002-9610(99)80068-3

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  23 in total

1.  Laparoscopic radiofrequency ablation of solitary hepatic gastrinoma metastases.

Authors:  Eldo Ermenegildo Frezza
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

Review 2.  Interventional neuroradiology of the head and neck.

Authors:  D Gandhi; J J Gemmete; S A Ansari; S K Gujar; S K Mukherji
Journal:  AJNR Am J Neuroradiol       Date:  2008-09-10       Impact factor: 3.825

3.  Percutaneous cryoablation in early stage hepatocellular carcinoma: analysis of local tumor progression factors.

Authors:  Dong Kyu Kim; Kichang Han; Jong Yun Won; Gyoung Min Kim; Joon Ho Kwon; Man Deuk Kim
Journal:  Diagn Interv Radiol       Date:  2020-03       Impact factor: 2.630

4.  Contrast-enhanced ultrasound (CEUS) follow-up after radiofrequency ablation or cryoablation of focal liver lesions: treated-area patterns and their changes over time.

Authors:  Aymeric Guibal; Caroline Bertin; Sophie Egels; Eric Savier; Philippe A Grenier; Olivier Lucidarme
Journal:  Eur Radiol       Date:  2012-11-09       Impact factor: 5.315

5.  Should hepatomas be treated with hepatic resection or transplantation?

Authors:  J Yamamoto; S Iwatsuki; T Kosuge; I Dvorchik; K Shimada; J W Marsh; S Yamasaki; T E Starzl
Journal:  Cancer       Date:  1999-10-01       Impact factor: 6.860

6.  Complement depletion enhances pulmonary inflammatory response after liver injury.

Authors:  Sean C Glasgow; Sathyabama Kanakasabai; Sabarinathan Ramachandran; T Mohanakumar; William C Chapman
Journal:  J Gastrointest Surg       Date:  2006-03       Impact factor: 3.452

7.  Large volume hepatic freezing: association with significant release of the cytokines interleukin-6 and tumor necrosis factor a in a rat model.

Authors:  Joachim K Seifert; Malcolm P France; Jing Zhao; Elaine J Bolton; Ian Finlay; Theodor Junginger; David L Morris
Journal:  World J Surg       Date:  2002-09-26       Impact factor: 3.352

8.  Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer.

Authors:  J K Seifert; D L Morris
Journal:  Ann Surg       Date:  1998-08       Impact factor: 12.969

9.  [Cryotherapy of liver metastases. Initial results].

Authors:  T Junginger; J K Seifert; T F Weigel; A Heintz; K F Kreitner; C D Gerharz
Journal:  Med Klin (Munich)       Date:  1998-09-15

10.  Percutaneous cryoablation in combination with ethanol injection for unresectable hepatocellular carcinoma.

Authors:  Ke-Cheng Xu; Li-Zhi Niu; Wei-Bin He; Zi-Qian Guo; Yi-Ze Hu; Jian-Sheng Zuo
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.